You searched for "PCa"
Demanding cases or nightmares in uro-oncology? Jan/Feb 2023
Radical surgical treatment of prostate cancer has become minimally invasive owing to robotic assisted laparoscopic technology [1]. Patients who undergo robotic assisted radical prostatectomy (RARP) often have lower risk of morbidity compared to an open approach. However, patients with a...
Adjuvant radiotherapy versus wait-and-see after radical prostatectomy
Optimum treatment modalities in prostate cancer continue to evolve, with debates at each stage of the evolution process, from focal therapy to radical treatment. In this randomised study, Wiegel et al. investigated the role of adjuvant radiotherapy following open radical...
Factors and time to conversion from prostate cancer active surveillance to treatment
Active surveillance is the standard of care for men with low-risk and selected men with favourable intermediate risk prostate cancer. The aim is to reduce the morbidity and mortality of overtreatment of non-clinically significant prostate cancer. A significant proportion progress...
Malignant upper urinary tract obstruction: emergency presentations and long-term outcomes
Malignant upper urinary tract obstruction (MUUTO) is a frequent emergency urological referral, often necessitating kidney drainage to preserve renal function. However, many patients have advanced cancer with limited life expectancy, raising questions about intervention benefits. While percutaneous nephrostomy (PCN) or...
Preoperative risk stratification of high-risk prostate cancer patients
High-risk prostate cancer (HRPCa) is associated with a significant risk of recurrence after radical treatment. While several classification systems exist, the D’Amico criteria – based on clinical T stage ≥T2c, prostate specific antigen (PSA) ≥20 ng/mL, or Gleason score (GS)...Rishi Sunak joins Prostate Cancer Research as an ambassador
Rishi Sunak with three prostate cancer patients at the Oxford BioDynamics labs. (From left to right: Dafydd Charles, Briane Milne, Rishi Sunak, Alfred Samuels). Former UK Prime Minister Rishi Sunak has joined Prostate Cancer Research as an ambassador, to champion...Prostate cancer
Case 1 What is prostate specific antigen (PSA) and what is its function? According to the ERSPC Trial (at 13 years), what was the number needed to screen and diagnosed to prevent one prostate cancer death and what was the...Updated guide on integrated paediatric continence services to significantly improve children’s lives and save NHS cost
The Paediatric Continence Forum has recently launched its updated Guide on how to commission and run integrated, nurse-led, community-based paediatric bladder and bowel (continence) services. These are clinically effective, improve the lives of children and their families and generate significant...
Performance of non-invasive tests in diagnosing BOO in men with LUTS
A large proportion of urology involves the treatment of bladder outflow obstruction (BOO) in men. Yet BOO in men is very difficult to accurately quantify with the only regular non-invasive test being uroflowmetry. Pressure flow urodynamics may be considered the...Demanding cases or nightmares in uro-oncology? Sep/Oct 2021
Active surveillance for prostate cancer: missing the boat Case In 2005 a 43-year-old man of Afro-Caribbean ethnicity was referred to our centre for investigation of suspected prostate cancer. Digital rectal exam revealed a firm right lobe, PSA of 2.3ng/ml, prostate...
ASAP: is a repeat biopsy necessary?
This study examined the validity of current US and European guidelines on the management of patients diagnosed with atypical small acinar proliferation (ASAP). Current guidance states that these patients should undergo repeat biopsy within three to six months due to...
